$126,977.34 research Payment -- Novartis Pharmaceuticals to Dr. Jeffrey Campbell
Novartis Pharmaceuticals invests over $126K in Neurology research for Eliquis with Dr. Jeffrey Campbell
This page provides a detailed analysis of a $126,977.34 research payment from Novartis Pharmaceuticals to Dr. Jeffrey Campbell. Data is from the CMS Open Payments (Sunshine Act) database.
Payment Details
| Field | Value |
|---|---|
| Amount | $126,977.34 |
| Payment Type | research |
| Payment Nature | Research |
| Pharmaceutical Company | Novartis Pharmaceuticals |
| Physician | Dr. Jeffrey Campbell |
| NPI Number | 1553630974 |
| Physician Specialty | Neurology |
| Location | Atlanta, GA |
| Date of Payment | 2024-10-26 |
| Related Drug/Device | Eliquis |
| Conflict Assessment | Moderate -- Worth Noting |
AI-Powered Analysis of This Payment
The following analysis was generated by artificial intelligence to help patients understand the context, significance, and implications of this pharmaceutical payment. This analysis is not medical or legal advice.
Novartis Pharmaceuticals made a $127.0K research payment to Jeffrey Campbell, a Neurology specialist in Atlanta, GA. The payment was associated with Eliquis. The total payment of $126,977.34 to Dr. Jeffrey Campbell is substantial, indicating significant investment in research activities. This payment is categorized as 'research,' suggesting it supports clinical trials or studies related to Novartis Pharmaceuticals' products. The payment was made for 'Eliquis,' a drug commonly used for preventing blood clots, aligning with the neurology specialty.
Patient Guidance: What This Payment Means for You
This payment supports research that may lead to new treatments or better understanding of neurological conditions. Ask your doctor if participating in a clinical trial is right for you. Always discuss your treatment options with your healthcare provider and ask about alternatives.
Payment Context: Is This Amount Normal?
Research payments can vary widely depending on the scope and duration of the study; this amount is significant but typical for large-scale clinical research.
Regulatory Context: Sunshine Act Requirements
Payments for research must be documented to ensure they are used for legitimate research activities and do not improperly influence prescribing practices.
Related Topics
This payment is related to the following healthcare transparency topics:
- pharmaceutical-payments
- research-funding
- neurology
- drug-development
- clinical-trials
- novartis
- eliquis
Understanding research Payments
Research payments fund clinical trials, research studies, and investigator-initiated research conducted by physicians. These payments are often the largest category and represent a critical part of the drug development process. Research funding is generally considered the most legitimate form of pharmaceutical payment, though potential conflicts of interest can still arise when researchers have financial relationships with the companies whose products they study.
Frequently Asked Questions About This Payment
What was this $127.0K payment for?
This was a research payment of $127.0K from Novartis Pharmaceuticals to Jeffrey Campbell, categorized as "Research". It was associated with Eliquis. The payment was reported under the Sunshine Act (CMS Open Payments).
Does Jeffrey Campbell accept pharmaceutical money?
Yes, Jeffrey Campbell received this $127.0K payment from Novartis Pharmaceuticals. Under the Sunshine Act, pharmaceutical companies must report all payments to physicians exceeding $10. You can view Jeffrey Campbell's full payment history on the CMS Open Payments database or on this site.
Is it legal for doctors to accept pharma payments?
Yes, it is legal for physicians to receive payments from pharmaceutical companies. The Physician Payments Sunshine Act (2010) requires transparency by mandating that companies report all payments exceeding $10 to CMS. These payments include consulting fees, meals, travel, speaking fees, and research grants. The law does not prohibit payments but ensures public disclosure.
Should I be concerned about this research payment?
A research payment of $127.0K typically funds clinical studies and is considered standard academic activity. Payment does not imply wrongdoing, but patients have the right to ask their doctor about pharmaceutical relationships.
How do I talk to my doctor about pharma relationships?
You can ask your doctor directly: "Do you receive payments from pharmaceutical companies?" and "Does this affect which medications you prescribe?" Most doctors will answer honestly. You can also verify payment data yourself through CMS Open Payments (openpaymentsdata.cms.gov). Consider asking about generic alternatives and whether the prescribed medication is the best option regardless of manufacturer relationships.
What types of pharma payments are most concerning?
Ownership interests and large consulting/speaking fees are generally considered more significant than meals or small educational grants. Research payments typically fund clinical studies and are common in academic medicine. The total volume and concentration of payments from a single company may be more telling than any individual payment. Patterns matter more than individual transactions.
Does pharma money affect what my doctor prescribes?
Research shows that even small payments can influence prescribing behavior. Studies published in JAMA Internal Medicine found that physicians who received meals costing as little as $20 were more likely to prescribe the promoted brand-name drug. However, many physician-industry interactions are legitimate professional activities. The key is transparency and awareness.
How does this compare to other doctors in Neurology?
To compare this payment against Neurology averages, check the full specialty breakdown on CMS Open Payments. Payment amounts vary widely by specialty and type. Neurology physicians may receive payments for consulting, speaking, or research that are standard for the field. Individual payments should be evaluated in the context of the doctor's full payment history.
What does this payment reveal about Jeffrey Campbell's relationship with Novartis Pharmaceuticals?
The payment date of October 26, 2024, falls within the current reporting period. This $127.0K research payment is part of the transparency data reported under the Sunshine Act.
Is this payment amount typical for Neurology?
Dr. Campbell's NPI (1553630974) is linked to this specific payment.
What should patients do after learning about this payment?
This payment supports research that may lead to new treatments or better understanding of neurological conditions. Ask your doctor if participating in a clinical trial is right for you.
What else should I know about this research payment?
The payment was processed through the Open Payments system, ensuring public transparency.
Related Reports
Data from CMS Open Payments. Payment does not imply wrongdoing. Consult your healthcare provider about any concerns.